• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOTRONIK AG, BUELACH, SWITZERLAND ORSIRO 3.0/18; CORONARY DRUG-ELUTING STENT SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOTRONIK AG, BUELACH, SWITZERLAND ORSIRO 3.0/18; CORONARY DRUG-ELUTING STENT SYSTEM Back to Search Results
Model Number 364490
Device Problem Fracture (1260)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 01/28/2020
Event Type  malfunction  
Event Description
An orsiro drug-eluting stent system was selected for treatment of a lesion in a proximal rca by direct stenting.After implantation the orsiro stent seemed fractured on the angiographic images.
 
Manufacturer Narrative
The complaint instrument was not returned to biotronik.Therefore, no technical investigation on the subject could be performed.The corresponding production documentation was reviewed to establish whether a deviation from the manufacturing process could be the cause for this event.In addition, screenshots taken from the angiographic material were reviewed.The screenshots taken from the angiographic material show the implantation of the complaint stent by direct stenting.Before post dilatation the outer surface of the stent does not seem to be smoothly open with a visible step in the stent outer contour.Finite element analysis was used to investigate further local material distribution effects, and a very similar step in the stent outer contour could be reproduced.After post-dilatation of the stent, the appearance of the outer contour seems to be much smoother.The presence of a stent fracture could not be confirmed.Review of the production documentation verified that the instrument was manufactured according to specifications and fulfilled all the requirements of in-process and final inspection.Based on the conducted investigations of the device being subject to this complaint, no material or manufacturing related root cause was determined.It might have been beneficial to have had the artery prepared with a non-compliant balloon before stenting.It should be noted that the corresponding ifu clearly advises the user that pre-dilatation of the lesion is mandatory.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ORSIRO 3.0/18
Type of Device
CORONARY DRUG-ELUTING STENT SYSTEM
Manufacturer (Section D)
BIOTRONIK AG, BUELACH, SWITZERLAND
ackerstrasse 6
buelach CH-81 80
CH  CH-8180
MDR Report Key9757313
MDR Text Key181363345
Report Number1028232-2020-00945
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
PMA/PMN Number
P170030
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Type of Report Initial,Followup
Report Date 02/25/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/26/2020
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date02/12/2021
Device Model Number364490
Device Catalogue NumberSEE MODEL NO.
Device Lot Number01194680
Was Device Available for Evaluation? No
Date Manufacturer Received05/07/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
-
-